Ravi Salgia to RNA, Small Interfering
This is a "connection" page, showing publications Ravi Salgia has written about RNA, Small Interfering.
Connection Strength
1.259
-
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005 Feb 15; 65(4):1479-88.
Score: 0.225
-
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192.
Score: 0.134
-
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Sci Rep. 2015 Jun 15; 5:10641.
Score: 0.115
-
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668.
Score: 0.100
-
Differential expression of RON in small and non-small cell lung cancers. Genes Chromosomes Cancer. 2012 Sep; 51(9):841-51.
Score: 0.093
-
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
Score: 0.075
-
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 2009 Mar; 89(3):301-14.
Score: 0.074
-
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer. 2007 Aug 06; 97(3):368-77.
Score: 0.067
-
c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007 Apr 01; 13(7):2246-53.
Score: 0.065
-
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 01; 66(1):352-61.
Score: 0.060
-
TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. Cancer Sci. 2017 Mar; 108(3):488-496.
Score: 0.032
-
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12.
Score: 0.028
-
AXL mediates resistance to cetuximab therapy. Cancer Res. 2014 Sep 15; 74(18):5152-64.
Score: 0.027
-
Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function. Am J Physiol Lung Cell Mol Physiol. 2013 Jul 01; 305(1):L56-63.
Score: 0.025
-
Critical role of S1PR1 and integrin ß4 in HGF/c-Met-mediated increases in vascular integrity. J Biol Chem. 2013 Jan 25; 288(4):2191-200.
Score: 0.024
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.022
-
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res. 2011 May 15; 17(10):3112-22.
Score: 0.021
-
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010 Oct 15; 285(42):32596-605.
Score: 0.020
-
PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res. 2010 Apr; 23(2):225-37.
Score: 0.020
-
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin. Cell Signal. 2007 Nov; 19(11):2329-38.
Score: 0.017
-
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9.
Score: 0.016